These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22910455)

  • 1. Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints.
    Xiao M; Wang Y; Yang QW; Fan X; Brown M; Kong F; Xu YC
    Int J Antimicrob Agents; 2012 Nov; 40(5):445-9. PubMed ID: 22910455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of the frequency of PER-1 type beta-lactamase and antimicrobial resistance rates in nosocomial isolates of Pseudomonas aeruginosa].
    Atilla A; Eroğlu C; Esen S; Sünbül M; Leblebicioğlu H
    Mikrobiyol Bul; 2012 Jan; 46(1):1-8. PubMed ID: 22399165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 16-year retrospective surveillance report on the pathogenic features and antimicrobial susceptibility of Pseudomonas aeruginosa isolates from FAHJU in Guangzhou representative of Southern China.
    Xie J; Yang L; Peters BM; Chen L; Chen D; Li B; Li L; Yu G; Xu Z; Shirtliff ME
    Microb Pathog; 2017 Sep; 110():37-41. PubMed ID: 28629721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.
    Raja NS; Singh NN
    J Microbiol Immunol Infect; 2007 Feb; 40(1):45-9. PubMed ID: 17332906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4606-10. PubMed ID: 15561832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
    Toh HS; Chuang YC; Huang CC; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Ko WC; Yu KW; Liu YC; Chen YS; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S18-23. PubMed ID: 22749054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
    Gad GF; El-Domany RA; Zaki S; Ashour HM
    J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance in Escherichia coli and Pseudomonas aeruginosa from Intensive Care Units in The Netherlands, 1998-2005.
    Oudhuis GJ; Verbon A; Hoogkamp-Korstanje JA; Stobberingh EE;
    Int J Antimicrob Agents; 2008 Jan; 31(1):58-63. PubMed ID: 17961989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metallo-beta-lactamase-mediated resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates].
    Mereuţă AI; Tuchiluş C; Bădescu AC; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1208-13. PubMed ID: 22276471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year report of national surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolated from non-tertiary care hospitals in Korea (2002-2006).
    Yoo J; Sohn ES; Chung GT; Lee EH; Lee KR; Park YK; Lee YS
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):291-4. PubMed ID: 18068936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong.
    Ho PL; Chow KH; Tse H; Cheng VC
    Int J Antimicrob Agents; 2012 Sep; 40(3):280-1. PubMed ID: 22795656
    [No Abstract]   [Full Text] [Related]  

  • 19. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa.
    Al-Jasser AM; Elkhizzi NA
    Saudi Med J; 2004 Jun; 25(6):780-4. PubMed ID: 15195211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003).
    Sánchez-Romero I; Cercenado E; Cuevas O; García-Escribano N; García-Martínez J; Bouza E;
    Rev Esp Quimioter; 2007 Jun; 20(2):222-9. PubMed ID: 17893760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.